Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection

Patent metadata

Field	Value
Publication number	US-10413611-B2
Application number	US-201815962458-A
Country	US
Kind code	B2
Filing date	Apr 25, 2018
Priority date	Nov 20, 2013
Publication date	Sep 17, 2019
Grant date	Sep 17, 2019

Abstract

The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising:
(a) at least one poloxamer selected from poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407, or a mixture thereof; and
(b) means for keeping the pharmaceutical composition in liquid phase up to a temperature of about 40° C. in vitro,
wherein the pharmaceutical composition is for use in submucosal lift of gastrointestinal mucosal lesions in a patient undergoing a gastrointestinal endoscopic procedure.

2. The pharmaceutical composition according to claim 1 , wherein the at least one poloxamer is poloxamer 124.

3. The pharmaceutical composition according to claim 1 , wherein the at least one poloxamer is poloxamer 188.

4. The pharmaceutical composition according to claim 1 , wherein the at least one poloxamer is poloxamer 237.

5. The pharmaceutical composition according to claim 1 , wherein the at least one poloxamer is poloxamer 338.

6. The pharmaceutical composition according to claim 1 , wherein the at least one poloxamer is poloxamer 407.

7. The pharmaceutical composition according to claim 1 , further comprising methylene blue or indigo carmine.

8. The pharmaceutical composition according to claim 1 , further comprising sodium chloride.

9. The pharmaceutical composition according to claim 1 , wherein the composition has a viscosity below about 150 centipoises.

10. The pharmaceutical composition according to claim 1 , wherein the composition has a viscosity below about 100 centipoises.

11. The pharmaceutical composition according to claim 1 , wherein the composition has a viscosity below about 50 centipoises.

12. The pharmaceutical composition according to claim 1 , wherein the composition has a viscosity below about 20 centipoises.

13. The pharmaceutical composition according to claim 1 , wherein the composition has a viscosity below about 10 centipoises.

14. The pharmaceutical composition according to claim 1 , wherein the gastrointestinal mucosal lesions are selected from inflammatory tissue, polyps, pseudo-polyps, flat polyps, serrated lesions, adenomas, ulcerations, dysplasias, pre-neoplastic and neoplastic formations, and tumors.

15. The pharmaceutical composition according to claim 1 , wherein the gastrointestinal endoscopic procedure is endoscopic mucosal resection or endoscopic submucosal dissection.

Assignees

• Cosmo Technologies Ltd
• Cosmo Tech Limited

Inventors

• Moro Luigi
• Longo Luigi Maria
• Frimonti Enrico
• Repici Alessandro

Classifications

• A61P41/00

  Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title

• A61L31/06

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)} · CPC title

• A61L2300/442

  Colorants, dyes · CPC title

• A61K9/1075

  Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence) · CPC title

• A61K47/22

  Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title